Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx ● Discussions with FDA advance toward expected marketing authorization for GraftAssureDx ● FDA completes current portion of substantive review in a timely manner ● Favorable M

Meta Platforms (META) stock fell 15.2% in October, closing at $614.99. S&P Global Ratings forecast a $71B cash flow deficit by 2027, lowering its outlook to negative. Analysts expect smaller deficits, with positive cash flow by 2029. Meta disputes S&P's AI monetization concerns. The company's mid-case target price is ~$1,222 by 2030, implying a 99% total return.

The US approved a $2.1B sale of 500 Patriot PAC-3 missiles to Ukraine, with deliveries potentially starting in a few years. President Zelenskyy welcomed the deal but urged faster delivery, citing urgent defense needs. The sale will be funded by Canada, Germany, Norway, and Ukraine, with Lockheed Martin as the contractor.

Meta settled with a second teen plaintiff in a social media addiction case, leaving Snap as the sole defendant in an upcoming trial. The plaintiffs allege Snap designed Snapchat to be addictive, causing mental and physical harm. Snap disputes these claims. Meta and other defendants previously settled similar cases, with terms undisclosed. The trial begins Nov. 4, with over 1,600 plaintiffs involved.

S&P Global Ratings changed Meta's (META) outlook to negative due to concerns over its AI investment spending and future cash flow, though its AA− credit rating remains unchanged. Meta forecasts $135-145B in capital expenditure for 2026, with Q3 operating cash flow at $32.79B and free cash flow at -$2.12B. Meta disputes S&P's concerns, citing potential AI revenue growth.

Intercontinental Exchange (ICE), the parent of the New York Stock Exchange, has agreed to bring Trade[XYZ]’s Hyperliquid perpetual futures to the U.S. pending regulatory approval. ICE will operate the markets and make a strategic investment, with Wall Street figure Stan Druckenmiller also investing. The native token HYPE rose ~20% on the news. The partnership aims to create a KYC-gated venue for trading perps on various assets, with ICE running the exchange and clearing.